he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
- 2022-04-27继发性癫痫的治疗法则 治疗癫痫病最常用的方式是什么
- 2022-04-13必须走出移动医疗「只圈地 轻盈利」怪圈
- 梅干腹 脑裂畸形1例
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办？
- Int J Urol：新的辅助化疗对机器人辅助根治性膀胱切除术后患者的生存和复发模式有影响
- 谁说生不出娃娃 是女人的错！？
- Sci Rep：可能参与睾丸生理调节
- 膀胱镜检查 膀胱镜术前准备和过程
- 简单而不简单的疾病:经典输尿管结石 1 病例
- 睡眠不好怎么办 睡眠不好竟然会关键时刻(2)
- 癫痫病食疗方法 药理学特色
- 苏州举办-药企实验室（研发/QC）规范管理与 ICH 手册 及药典最新进展」研修班
- 猪血的做法 老少皆宜的补血绿豆(14)
- 38年病史的痉挛患者一封感谢信 道出浓浓医患情